Liver function monitoring indicators and recommendations during Opicapone treatment

Opicapone is a peripheral COMT inhibitor used in patients with Parkinson's disease. It is often used in combination with levodopa to extend the action time of levodopa and improve the therapeutic effect. Although it is generally well tolerated, liver function monitoring is still very important during treatment because drug metabolism mainly depends on the liver, and abnormal liver function may lead to drug accumulation or aggravate adverse reactions, thus affecting the safety of treatment.

In terms of liver function monitoring, the core indicators include alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL) and alkaline phosphatase (ALP). These indicators can reflect liver cell damage, cholestasis and overall liver metabolic function. Before starting treatment with Opicapone, it is recommended to conduct a baseline liver function test to determine whether the patient has chronic liver disease or potential abnormal liver function, so that changes in liver function can be accurately judged during the medication.

During the course of medication, it is recommended to review liver function indicators regularly. Generally, follow-up monitoring can be performed during the first and third months of treatment and every three to six months thereafter. If ALT or AST is found to be significantly elevated, or total bilirubin is abnormal, the clinical symptoms should be considered to evaluate whether to continue using Opicapone. If the liver function index exceeds the upper limit of normal by more than 3 times or obvious jaundice occurs, the drug dosage should be suspended or adjusted, and further liver function tests should be performed to prevent serious liver damage.

In addition, patients and family members should also pay attention to liver health management in their daily lives. Avoid using other drugs or health products that may damage the liver at the same time, control alcohol consumption, maintain a reasonable diet, and promptly report symptoms such as fatigue, loss of appetite, nausea, jaundice, or deepened urine to your doctor. Through the combination of baseline assessment, regular reexamination and daily care, the potential risks of opicapone to liver function during treatment can be effectively reduced, ensuring the safety of medication and obtaining the best therapeutic effect for patients with Parkinson's disease.

Reference materials:https://www.drugs.com/